Skip to main content

Advertisement

SpringerLink
Log in

Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Recent discoveries regarding the relatively autonomous workings of the enteric nervous system have expanded our understanding of the pathophysiology of irritable bowel syndrome (IBS). However, the heterogeneity of the pathogenesis of IBS continues to create unique challenges for clinicians who care for these patients. Advances in our understanding of the structure and functions of the braingut axis and its interplay with other potentially important factors, such as genetic predisposition, inflammation, and psychological unrest, have led to new developments in the field of targeted pharmacotherapy for IBS sufferers. Therapies designed specifically to modulate gut motility, secretion, and/or sensation have been created and introduced into the marketplace in recent years, and additional designer formulations are in various stages of development. Concurrently, new discoveries of potentially beneficial effects of agents approved for other, often nongastroenterologic, conditions continue to be reported. This article reviews the accumulating body of evidence supporting the importance of neuromuscular dysfunction as a central cause of IBS symptoms and provides a rationale for the discussion of current and future drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Talley NJ, Gabriel SE, Harmsen WS, et al.: Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995, 109:1736–1741.

    Article  PubMed  CAS  Google Scholar 

  2. Goodman C, Cronin K, Gemmen E, et al.: In The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association, 2001:2–65.

    Google Scholar 

  3. Drossman DA, Lesserman J, Nachman G, et al.: Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990, 113:828–833.

    PubMed  CAS  Google Scholar 

  4. Camilleri M: Motor function in irritable bowel syndrome. Can J Gastroenterol 1999, 13(Suppl A):8A-11A.

    PubMed  Google Scholar 

  5. Bouin M, Plourde V, Boivin M, et al.: Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002, 122:1771–1777.

    Article  PubMed  Google Scholar 

  6. Lawal A, Kern M, Sidhu H, et al.: Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006, 130:26–33. Novel study of visceral and central nervous system processing in IBS patients in which subliminal rectal distention was performed in IBS patients and asymptomatic controls. IBS patients were demonstrated to exhibit lower distention thresholds and differential central nervous system processing of the distention. This is the first study to demonstrate such findings without potential cognitive bias.

    Article  PubMed  Google Scholar 

  7. Kalantar JS, Locke III GR, Zinsmeister AR, et al.: Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003, 52:1703–1707.

    Article  PubMed  CAS  Google Scholar 

  8. Levy RL, Jones KR, Whitehead WE, et al.: Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001, 121:799–804.

    Article  PubMed  CAS  Google Scholar 

  9. Saito YA, Petersen GM, Locke GR III, et al.: The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005, 3:1057–1065.

    Article  PubMed  CAS  Google Scholar 

  10. Ohman L, Isaksson S, Lundgren A, et al.: A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:980–986.

    Article  PubMed  Google Scholar 

  11. Tornblom H, Lindberg G, Nyberg B, et al.: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972–1979.

    Article  PubMed  Google Scholar 

  12. Spiller RC: Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004, 2:445–455.

    Article  PubMed  Google Scholar 

  13. Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503–3506.

    Article  Google Scholar 

  14. Spiegel BM, DeRosa VP, Gralnek IM, et al.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004, 126:1721–1732.

    Article  PubMed  Google Scholar 

  15. Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733–1740.

    Article  PubMed  CAS  Google Scholar 

  16. Jones R, Holtmann G, Rodrigi L, et al.: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999, 13:1419–1427.

    Article  PubMed  CAS  Google Scholar 

  17. Mayer EA, Berman S, Derbyshire SWG, et al.: The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002, 16:1357–1366.

    Article  PubMed  CAS  Google Scholar 

  18. Chey WD, Cash BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 2005, 14:1–9.

    Article  Google Scholar 

  19. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16:877–888.

    Article  Google Scholar 

  20. Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671–676. Large randomized placebo-controlled trial carried out in Asia-Pacific of tegaserod in patients with non-diarrheal IBS that demonstrated statistically significant benefit for overall IBS symptoms and individual symptoms, such as abdominal bloating and constipation.

    Article  PubMed  CAS  Google Scholar 

  21. Bottoli I, Tougas G, Dunger-Baldauf C, et al.: Efficacy of tegaserod over 12 months in IBS-C patients: Do responders at month 3 still respond at month 12? Gastroenterology 2005, 128:A463–464.

    Article  Google Scholar 

  22. Camilleri M, McKinzie S, Fox J, et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004, 2: 895–904.

    Article  PubMed  CAS  Google Scholar 

  23. Liu Z, Sakakibara R, Odaka T, et al.: Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005, 20: 680–686.

    Article  PubMed  Google Scholar 

  24. Song GH, Leng, PH, Gwee, KA, et al.: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double-blind, placebo controlled trial. Gut 2005, 54:1402–1407.

    Article  PubMed  CAS  Google Scholar 

  25. Lu WX, Gwee KA, Moochhalla S, et al.: Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 22:927–934.

    Article  PubMed  CAS  Google Scholar 

  26. Jackson JL, O’Malley PG, Tomkins G, et al.: Treatment of functional bowel gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65–72.

    Article  PubMed  CAS  Google Scholar 

  27. Drossman DA, Toner BB, Whitehead WE, et al.: Cognitivebehavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19–31. This is the most rigorous study to date of the effects of a tricyclic antidepressant for IBS. This study demonstrated that desipramine is superior to placebo for the relief of the symptoms of IBS only when patients with significant side effects are excluded from the analysis.

    Article  PubMed  Google Scholar 

  28. Morgan V, Pickens D, Gautam S, et al.: Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005, 545:601–607.

    Article  CAS  Google Scholar 

  29. Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303–317.

    Article  PubMed  Google Scholar 

  30. Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-.ber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914–920.

    Article  PubMed  CAS  Google Scholar 

  31. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003, 1:219–228.

    Article  PubMed  CAS  Google Scholar 

  32. Vahedi H, Merat S, Rashidioon A, et al.: The effect of fluoxetine in patients with pain and constipationpredominant irritable bowel syndrome: a double blind randomized-controlled study. Aliment Pharmacol Ther 2005, 22:381–385.

    Article  PubMed  CAS  Google Scholar 

  33. Masand PS, Gupta S, Scwartz TL, et al.: Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005, 7:162–6.

    PubMed  Google Scholar 

  34. Tack J, Broekaert D, Fischler B, et al.: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 Jan 9, [Epub ahead of print].

  35. Fukudo S, Namura T, Hongo M: Impact of corticotrophin-releasing hormone on gastrointestinal motility and adrenocorticotrophic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998, 42:845–849.

    Article  PubMed  CAS  Google Scholar 

  36. Sagami Y, Shimada Y, Tayama J, et al.: Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53:958–964.

    Article  PubMed  CAS  Google Scholar 

  37. Camilleri M: Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005, 17:157–165.

    Article  PubMed  CAS  Google Scholar 

  38. Gonenne J, Camilleri M, Ferber I: Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005, 3:784–791.

    Article  PubMed  CAS  Google Scholar 

  39. Viscusi ER, Goldstein S, Witkowski T, et al.: Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006, 20:64–70.

    Article  PubMed  CAS  Google Scholar 

  40. Delaney CP, Weese JL, Hyman NH, et al.: Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005, 48:1114–1125.

    Article  PubMed  Google Scholar 

  41. Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a σ opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2002, 284:G558-G566.

    Google Scholar 

  42. Delvaux M, Beck A, Jacob J, et al.: Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distention in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:237–246.

    Article  PubMed  CAS  Google Scholar 

  43. Lordal M, Navalesi G, Theodornsson E, et al.: A novel tachykinin NK2 receptor antagonist prevents motilitystimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001, 134:215–223.

    Article  PubMed  CAS  Google Scholar 

  44. Viramontes BE, Malcolm A, Camilleri M, et al.: Effects of α2-adrenergic agonist on gastrointestinal transit, colonic motility and sensation in humans. Am J Physiol 2001, 281:G1468-G1476.

    CAS  Google Scholar 

  45. Camilleri M, Kim D-Y, McKinzie S, et al.: A randomized, controlled exploratory study of clonidine in diarrheapredominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003, 1:111–121.

    Article  PubMed  CAS  Google Scholar 

  46. Leventer S, Raudibaugh K, Frissora C, et al.: The safety and efficacy of dextofisopam in patients with diarrheapredominant or alternating irritable bowel syndrome. Gastroenterology 2005, 128:A94.

    Google Scholar 

  47. Johanson JF, Gargano MA, Holland PC, et al.: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology 2003, 124:A48.

    Article  Google Scholar 

  48. Johanson JF, Gargano MA, Holland PC, et al.: Multicenter open-label study of oral lubiprostone for the treatment of chronic constipation. Am J Gastroenterol 2005, 100:S331.

    Google Scholar 

  49. Eutamene H, Theodorou V, Tondereau V, et al.: Influence of guanylate cyclase C binding ligand MD-1100 on TNBS-induced visceral hypersensitivity in WT vs. KO guanylate cyclase C deficient mice. Gastroenterology 2006, 130(Suppl 2):A597.

    Google Scholar 

  50. Kurtz C, Fitch D, Busby RW, et al.: Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 2006, 130(Suppl 2):A26.

    Google Scholar 

  51. Cash BD, Chey WD: Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005, 22:1047–1060.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, 48109-0362, Ann Arbor, MI, USA

    William D. Chey MD

Authors
  1. William D. Chey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brooks D. Cash MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William D. Chey MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chey, W.D., Cash, B.D. Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment. Curr Gastroenterol Rep 8, 273–281 (2006). https://doi.org/10.1007/s11894-006-0047-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-006-0047-z

Keywords

Search

Navigation